366 related articles for article (PubMed ID: 14523023)
1. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism.
Bellido T; Ali AA; Plotkin LI; Fu Q; Gubrij I; Roberson PK; Weinstein RS; O'Brien CA; Manolagas SC; Jilka RL
J Biol Chem; 2003 Dec; 278(50):50259-72. PubMed ID: 14523023
[TBL] [Abstract][Full Text] [Related]
2. Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein.
Fu Q; Jilka RL; Manolagas SC; O'Brien CA
J Biol Chem; 2002 Dec; 277(50):48868-75. PubMed ID: 12364326
[TBL] [Abstract][Full Text] [Related]
3. Reactive oxygen species stimulates receptor activator of NF-kappaB ligand expression in osteoblast.
Bai XC; Lu D; Liu AL; Zhang ZM; Li XM; Zou ZP; Zeng WS; Cheng BL; Luo SQ
J Biol Chem; 2005 Apr; 280(17):17497-506. PubMed ID: 15731115
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts.
Kaneki H; Guo R; Chen D; Yao Z; Schwarz EM; Zhang YE; Boyce BF; Xing L
J Biol Chem; 2006 Feb; 281(7):4326-33. PubMed ID: 16373342
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D and dexamethasone inversely regulate parathyroid hormone-induced regulator of G protein signaling-2 expression in osteoblast-like cells.
Hömme M; Schmitt CP; Himmele R; Hoffmann GF; Mehls O; Schaefer F
Endocrinology; 2003 Jun; 144(6):2496-504. PubMed ID: 12746312
[TBL] [Abstract][Full Text] [Related]
6. Parathyroid hormone-Smad3 axis exerts anti-apoptotic action and augments anabolic action of transforming growth factor beta in osteoblasts.
Sowa H; Kaji H; Iu MF; Tsukamoto T; Sugimoto T; Chihara K
J Biol Chem; 2003 Dec; 278(52):52240-52. PubMed ID: 14517210
[TBL] [Abstract][Full Text] [Related]
7. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone.
Locklin RM; Khosla S; Turner RT; Riggs BL
J Cell Biochem; 2003 May; 89(1):180-90. PubMed ID: 12682918
[TBL] [Abstract][Full Text] [Related]
8. Parathyroid hormone regulates osterix and Runx2 mRNA expression predominantly through protein kinase A signaling in osteoblast-like cells.
Wang BL; Dai CL; Quan JX; Zhu ZF; Zheng F; Zhang HX; Guo SY; Guo G; Zhang JY; Qiu MC
J Endocrinol Invest; 2006 Feb; 29(2):101-8. PubMed ID: 16610234
[TBL] [Abstract][Full Text] [Related]
9. The Proteasome Inhibitor Carfilzomib Suppresses Parathyroid Hormone-induced Osteoclastogenesis through a RANKL-mediated Signaling Pathway.
Yang Y; Blair HC; Shapiro IM; Wang B
J Biol Chem; 2015 Jul; 290(27):16918-28. PubMed ID: 25979341
[TBL] [Abstract][Full Text] [Related]
10. Skeletal unloading alleviates the anabolic action of intermittent PTH(1-34) in mouse tibia in association with inhibition of PTH-induced increase in c-fos mRNA in bone marrow cells.
Tanaka S; Sakai A; Tanaka M; Otomo H; Okimoto N; Sakata T; Nakamura T
J Bone Miner Res; 2004 Nov; 19(11):1813-20. PubMed ID: 15476581
[TBL] [Abstract][Full Text] [Related]
11. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis.
Bellido T; Ali AA; Gubrij I; Plotkin LI; Fu Q; O'Brien CA; Manolagas SC; Jilka RL
Endocrinology; 2005 Nov; 146(11):4577-83. PubMed ID: 16081646
[TBL] [Abstract][Full Text] [Related]
12. Parathyroid hormone induction of the osteocalcin gene. Requirement for an osteoblast-specific element 1 sequence in the promoter and involvement of multiple-signaling pathways.
Jiang D; Franceschi RT; Boules H; Xiao G
J Biol Chem; 2004 Feb; 279(7):5329-37. PubMed ID: 14634012
[TBL] [Abstract][Full Text] [Related]
13. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.
Kondo H; Guo J; Bringhurst FR
J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of osteoblast-specific transcription factor Cbfa1 by the cAMP pathway in osteoblastic cells. Ubiquitin/proteasome-dependent regulation.
Tintut Y; Parhami F; Le V; Karsenty G; Demer LL
J Biol Chem; 1999 Oct; 274(41):28875-9. PubMed ID: 10506130
[TBL] [Abstract][Full Text] [Related]
15. Regulation of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase a pathway in murine bone marrow cultures.
Lee SK; Lorenzo JA
Bone; 2002 Jul; 31(1):252-9. PubMed ID: 12110442
[TBL] [Abstract][Full Text] [Related]
16. Endogenous FGF-2 is critically important in PTH anabolic effects on bone.
Sabbieti MG; Agas D; Xiao L; Marchetti L; Coffin JD; Doetschman T; Hurley MM
J Cell Physiol; 2009 Apr; 219(1):143-51. PubMed ID: 19107841
[TBL] [Abstract][Full Text] [Related]
17. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.
Lee SK; Lorenzo JA
Endocrinology; 1999 Aug; 140(8):3552-61. PubMed ID: 10433211
[TBL] [Abstract][Full Text] [Related]
18. Targeted overexpression of G protein-coupled receptor kinase-2 in osteoblasts promotes bone loss.
Wang L; Liu S; Quarles LD; Spurney RF
Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E826-34. PubMed ID: 15585587
[TBL] [Abstract][Full Text] [Related]
19. Amphiregulin-EGFR signaling mediates the migration of bone marrow mesenchymal progenitors toward PTH-stimulated osteoblasts and osteocytes.
Zhu J; Siclari VA; Liu F; Spatz JM; Chandra A; Divieti Pajevic P; Qin L
PLoS One; 2012; 7(12):e50099. PubMed ID: 23300521
[TBL] [Abstract][Full Text] [Related]
20. Parathyroid hormone (1-34) counteracts the suppression of interleukin-11 expression by glucocorticoid in murine osteoblasts: a possible mechanism for stimulating osteoblast differentiation against glucocorticoid excess.
Kuriwaka-Kido R; Kido S; Miyatani Y; Ito Y; Kondo T; Omatsu T; Dong B; Endo I; Miyamoto K; Matsumoto T
Endocrinology; 2013 Mar; 154(3):1156-67. PubMed ID: 23397032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
